Merck & Company Inc (MRK)

$129.90

up-down-arrow $-0.46 (-0.35%)

As on 30-Jul-2026 15:46EDT

Market cap

info icon

$307,246 Mln

Revenue (TTM)

info icon

$65,593 Mln

P/E Ratio

info icon

35.9

P/B Ratio

info icon

6.9

Div. Yield

info icon

2.6 %

Merck & Company Inc (MRK) Share Price

Compare

High: Low: Return:

Max: Min: Median:

Max: Min: Median:

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 127.25 High: 130.21

52 Week Range

Low: 77.53 High: 135.05

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $13,175 Mln

  • ROEROE information

    0.2 %

  • ROCEROCE information

    19.4 %

  • Industry P/EIndustry P/E information

    33.68

  • EV/EBITDAEV/EBITDA information

    18.5

  • Debt to EquityDebt to Equity information

    1

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $3.6

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    2,469,824,415

10 Years Aggregate

CFO

$117,929.00 Mln

EBITDA

$115,983.00 Mln

Net Profit

$75,684.00 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Merck & Company Inc (MRK)
23.4 0.4 17.1 57.2 6.9 11.0 8.8
BSE Sensex
-8.0 1.6 0.6 -4.2 5.6 8.2 10.8
S&P 100
5.9 1.0 3.9 16.8 19.6 12.5 14.3
As on 30-Jul-2026
Company
2025
2024
2023
2022
2021
2020
2019
Merck & Company Inc (MRK)
5.8 -8.7 -1.7 44.8 1.9 -7.1 22.4
S&P 100
18.7 29.0 30.8 -22.1 27.6 19.3 29.5
BSE Sensex
9.1 8.1 18.7 4.4 22.0 15.8 14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Merck & Company Inc (MRK)
129.9 307,246.2 65,593.0 8,935.0 19.3 18.3 35.9 6.9
259.3 453,924.5 62,819.0 3,639.0 14.1 -- 123.5 50.5
387.5 202,951.9 37,238.0 7,800.0 31.7 82.9 25.8 21.8
64.8 126,792.2 48,482.0 7,275.0 21.6 37.7 17.4 6.3
1,159.2 1,057,489.4 72,249.5 25,275.0 44.1 91.9 41.3 33.2
130.9 160,547.4 29,734.0 9,216.0 39.5 40.9 17.8 6.9
255.7 624,119.1 97,929.0 21,037.0 19.4 25.3 29.7 7.6
866.0 96,529.4 403,430.0 4,762.0 1.6 -246.4 21.2 5.0
24.9 141,061.2 63,315.0 7,491.0 16.7 8.1 18.9 1.6
42.5 104,823.1 47,354.0 7,555.0 19.6 10.3 19.2 1.3

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Merck & Company Inc (MRK)

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23,...  Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey. 

  • Chairman, President & CEO

    Mr. Robert M. Davis J.D.

  • Chairman, President & CEO

    Mr. Robert M. Davis J.D.

  • Headquarters

    Rahway, NJ

  • Website

    https://www.merck.com

Edit peer-selector-edit
loading...
loading...

FAQs for Merck & Company Inc (MRK)

The share price of Merck & Company Inc (MRK) is $129.90 (NYSE) as of 30-Jul-2026 15:46 EDT. Merck & Company Inc (MRK) has given a return of 6.9% in the last 3 years.

The P/E ratio of Merck & Company Inc (MRK) is 35.94 times as on 24-Jul-2026, a 7 premium to its peers’ median range of 33.68 times.
The P/B ratio of Merck & Company Inc (MRK) is 6.86 times as on 24-Jul-2026, a 0 premium to its peers’ median range of 6.86 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2025
14.35
4.98
2024
14.77
5.46
2023
762.89
7.41
2022
19.47
6.15
2021
14.89
5.09

The 52-week high and low of Merck & Company Inc (MRK) are Rs 135.05 and Rs 77.53 as of 31-Jul-2026.

Merck & Company Inc (MRK) has a market capitalisation of $ 307,246 Mln as on 24-Jul-2026. As per SEBI classification, it is a Large Cap company.

Before investing in Merck & Company Inc (MRK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.